Palo Alto Investors LP Takes $3.04 Billion Position in Edwards Lifesciences Corporation $EW

Palo Alto Investors LP bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 33,640 shares of the medical research company’s stock, valued at approximately $3,043,074,000.

A number of other institutional investors have also made changes to their positions in EW. TrinityBridge Ltd bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $27,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the first quarter worth $25,000. Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences during the fourth quarter worth $27,000. Finally, JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $25,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,857 shares of company stock valued at $170,305 in the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on EW. Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Performance

EW opened at $89.97 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business has a fifty day simple moving average of $89.48 and a 200 day simple moving average of $84.99. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a market capitalization of $51.81 billion, a PE ratio of 51.71, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the business earned $0.67 EPS. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.